Area of research
Epidemiology · Oncology
Research interest
Research interests include Cervical Cancer and HPV Research, Global Cancer Incidence and Screening, Endometrial and Cervical Cancer Treatments, and Reproductive tract infections research.
Lessons Learned From Evaluation of a Human Papillomavirus Screening Pilot in Uzbekistan.
From evidence to action: the IARC's role in strengthening cancer prevention and early detection.
Analysis of time trends of prevalence of high-risk HPV infections, high grade cervical precancer and cervical cancer disease in women from Eastern India over 20 years - Pooled analysis from three studies.
Use of Thermal Ablation in Low-Resource Settings: Experience From Three Multicenter Noninferiority Randomized Clinical Trials.
Can we increase the cervical cancer screening interval with an HPV test for women living with HIV? Results of a cohort study from Maharashtra, India.
The journey of cancer patients and the quest to equity: findings from Morocco.
Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccine
Agreement between Self- and Physician‑Sampling for Detection of High‑Risk Human Papillomavirus Infections in Women Attending Cervical Screening at National Cancer Institute, Thailand.
Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination
Comparing one dose of HPV vaccine in girls aged 9–14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial
Effectiveness of Artificial Intelligence-Assisted Decision-making to Improve Vulnerable Women's Participation in Cervical Cancer Screening in France: Protocol for a Cluster Randomized Controlled Trial (AppDate-You).
Efficacy and safety of therapeutic HPV vaccines to treat CIN 2/CIN 3 lesions: a systematic review and meta-analysis of phase II/III clinical trials
Risk-Based Selection of Individuals for Oral Cancer Screening.
Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years – updated evidence from Indian follow-up cohort study
Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study
Are two doses of human papillomavirus vaccine sufficient for girls aged 15–18 years? Results from a cohort study in India
Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study
Breast cancer in pre-menopausal women in West Africa: Analysis of temporal trends and evaluation of risk factors associated with reproductive life